Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis

NAEnrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 23, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Healthy SubjectsRheumatoid ArthritisVasculitisPulmonary Sarcoidosis

Interventions

OTHER

[68Ga]Ga-DOTA-Siglec-9

Vascular Adhesion Protein 1 (VAP-1) targeted radiopharmaceutical

Trial Locations (1)

Turku University Hospital, Turku PET Centre, Turku

All Listed Sponsors

lead

Turku University Hospital

OTHER_GOV